Skip to main content
Erschienen in: Reactions Weekly 1/2015

01.05.2015 | Case report

Alemtuzumab

Transformation of Sézary syndrome into CD30 + anaplastic large T-cell lymphoma: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (FDA MedWatch definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * requires intervention to prevent permanent impairment or damage
Literatur
Zurück zum Zitat Nevet MJ, et al. Transformation of sezary syndrome into CD30+ anaplastic large T-Cell lymphoma after alemtuzumab therapy with evidence of clonal unity. American Journal of Dermatopathology 37: 73-77, No. 1, 1 Jan 2015 - IsraelCrossRefPubMed Nevet MJ, et al. Transformation of sezary syndrome into CD30+ anaplastic large T-Cell lymphoma after alemtuzumab therapy with evidence of clonal unity. American Journal of Dermatopathology 37: 73-77, No. 1, 1 Jan 2015 - IsraelCrossRefPubMed
Metadaten
Titel
Alemtuzumab
Transformation of Sézary syndrome into CD30 + anaplastic large T-cell lymphoma: case report
Publikationsdatum
01.05.2015
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2015
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-015-1791-3

Weitere Artikel der Ausgabe 1/2015

Reactions Weekly 1/2015 Zur Ausgabe

Case report

Atomoxetine

Case report

Topiramate

Case report

Tenofovir

Case report

Bortezomib